Ry Guy News

Enrollment in our Phase 1/2 clinical study in Ewing and other FET-rearranged sarcomas is progressing well. We recently announced the addition of several prestigious institutions to the study, bringing the total to 17 clinical trial sites with 25 separate locations. During July and August we added the Seattle Cancer Care Alliance, which is comprised of the Fred Hutchinson Cancer Research Center, Seattle Children's Hospital and the University of Washington Medical Center, along with Oregon Health & Sciences University, the Mayo Clinic in Rochester, Minnesota and the Mayo Clinic in Jacksonville, Florida. These are all well-known and highly regarded cancer research centers that join the cadre of existing sites that are active and enrolling patients in the sarcoma trial, and while we might add more sites in the future, the initiation of sites for this study is now largely complete. We remain on track to report interim sarcoma data later this year, with additional data being available as patients continue to enroll and are treated with seclidemstat. As a reminder, Ewing and FET-rearranged sarcomas are rare cancers and patients face limited treatment options and poor prognoses. At the recent American Society of Clinical Oncology annual meeting (ASCO), results from the rEECur study (a randomized trial evaluating first- and second- Ewing relapse treatments) found that patients treated with topotecan plus cyclophosphamide demonstrated progression-free survival of only 3.5 months, and patients treated with high-dose ifosfamide demonstrated only 5.7 months of progression-free survival.1 We believe these Ewing patients need improved treatment options and that delaying disease progression or improving progression-free survival is a significant patient benefit. With the help of our investigators, we have enrolled a number of patients with first- and second- relapsed Ewing sarcoma, we are treating these patients with a combination of topotecan, cyclophosphamide and seclidemstat and we are tracking these patients’ time to progression, duration of treatment and other key measures of long-term benefit. We look forward to sharing interim data later this year. All of us at Salarius are motivated by the prospect of making a difference in the lives of patients battling these cancers with high unmet need.